Detalhe da pesquisa
1.
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Lancet
; 401(10374): 347-356, 2023 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36739136
2.
The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity.
Hum Genomics
; 17(1): 99, 2023 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946254
3.
The Role of Gender Pharmacogenetics in the Personalization of Drug Treatment.
J Pharmacol Exp Ther
; 386(2): 190-197, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37001987
4.
Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study.
Pharmacol Res
; 197: 106949, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37802427
5.
Implementation of pre-emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?
Br J Clin Pharmacol
; 2023 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37926674
6.
CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients.
Br J Clin Pharmacol
; 89(3): 1089-1098, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36178950
7.
Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis.
Int J Mol Sci
; 24(4)2023 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36834713
8.
Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.
Br J Cancer
; 126(4): 640-651, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34703007
9.
Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity.
Am J Hum Genet
; 104(6): 1158-1168, 2019 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31155283
10.
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
Drug Resist Updat
; 51: 100702, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32371296
11.
Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study.
Pharmacogenet Genomics
; 30(6): 131-144, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32317559
12.
A TGF-ß associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
Gynecol Oncol
; 156(1): 233-242, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31711657
13.
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions.
Int J Mol Sci
; 21(17)2020 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32883002
14.
Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Drug Resist Updat
; 39: 18-40, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30075835
15.
Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy Outcomes.
Int J Mol Sci
; 20(21)2019 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31694149
16.
rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy.
Int J Mol Sci
; 20(9)2019 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31035590
17.
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS).
Int J Mol Sci
; 19(5)2018 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29783665
18.
UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population.
Liver Int
; 37(9): 1345-1353, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28294511
19.
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.
Int J Mol Sci
; 18(7)2017 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28708103
20.
HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.
Int J Mol Sci
; 18(7)2017 Jun 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28653974